SGLT-2 and DPP-4 Inhibition, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections.

Plain-language summary

This study examined how SGLT-2 and DPP-4 inhibitor drugs (Empagliflozin, Dapagliflozin, Linagliptin, Saxagliptin) affect low-grade (subclinical) inflammation of the genito-urinary tract and the risk of infections in patients with type 2 diabetes. People with type 2 diabetes whose HbA1c was between 7% and 9% could take part. This study without an assigned phase has been carried out and is completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

University of Pisa

Intervention

Empagliflozin / Linagliptin or Dapagliflozin/Saxagliptin Pill, Empagliflozin or Dapagliflozin Pill

Start date

10/7/2020

Estimated completion

4/7/2022

Countries

Italy

Related genes

Locations

• Pisa, Italy

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Type 2 diabetes diagnosis
* Hb1Ac ≥ 7% and ≤ 9%

Exclusion Criteria:

* Hb1Ac \> 9%
* current treatment with an SGLT2i or a DPP4i drugs, or in the prior 4 week
* irritating and/or obstructive urinary or genital symptoms
* menstrual cycle for women
* current antibiotic treatment or in the prior 4 weeks
* anatomical or functional abnormalities of the urinary tract (e.g. incontinence, neurological bladder, bladder prolapse).